Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.
Age ≥ 50 years old;
The participant can provide personal informed consent and sign the informed consent form;
temperature ≤ 37.0℃ on the day of administration;
capable of complying with the requirements of the clinical trial protocol to complete the trial.
Subjects with immunodeficiency or immunosuppression caused by underlying diseases or treatments, including primary/acquired immunodeficiency (e.g., AIDS and other virus-induced immunodeficiency), hematologic malignancies (leukemia, lymphoma or other bone marrow/lymphoid neoplasms), ongoing immunosuppressive therapy, or radiotherapy/chemotherapy for malignancies.
Subjects with a history of allergic reaction to any component of the investigational product.
Subjects with acute infection or acute exacerbation of chronic infection (vaccination should be deferred).
Women of non-postmenopausal status with positive pregnancy test, pregnant or lactating women, or those planning pregnancy within 6 months.
Single group
live-attenuated zoster vaccine
Biological/Vaccineone dose of live-attenuated zoster vaccine to the particpent only administered one dose of recombinant zoster vaccine
immunogenicity
IgG to gE/FAMA antibody/Cellular immune level
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
